問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚儒

Recruiting

List

72Cases

2026-02-23 - 2032-12-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-06-01 - 2032-02-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-08-01 - 2021-09-10

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-07-15 - 2022-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

2023-06-01 - 2030-03-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-06-01 - 2028-11-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2026-01-15 - 2043-05-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-11-01 - 2024-09-30

Phase I

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    H3B-8800 (RVT-2001)

Participate Sites
5Sites

Recruiting5Sites

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2016-07-31 - 2022-06-30

Phase II/III

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB